Last quarter (Q4 2022), COSMO Pharmaceuticals N.V.'s total revenue was €―, a decrease of ― from the same quarter last year. In Q4, COSMO Pharmaceuticals N.V.'s net income was €―. See COSMO Pharmaceuticals N.V.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 102.09M	€ 65.07M	€ 60.95M	€ 62.49M	€ 65.62M
Cost of Revenue	-	€ 18.76M	€ 15.14M	€ 10.44M	€ 9.25M	€ 6.22M
Gross Profit	-	€ 83.33M	€ 49.93M	€ 50.51M	€ 53.25M	€ 59.40M
Operating Expense	-	€ 55.27M	€ 38.83M	€ 43.60M	€ 65.56M	€ 76.02M
Operating Income	-	€ 28.06M	€ 11.10M	€ 6.91M	€ -12.31M	€ -16.62M
Net Non Operating Interest Income Expense	-	€ -6.33M	€ -6.41M	€ -7.16M	€ -7.75M	€ 1.15M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ 24.47M	€ 24.00M	€ -6.93M	€ -21.30M	€ -17.46M
Tax Provision	-	€ 6.97M	€ 2.33M	€ 970.00K	€ 3.19M	€ 598.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ 17.23M	€ 21.67M	€ -7.90M	€ -24.42M	€ -18.01M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	€ 120.00K	€ 117.00K	€ 102.00K	€ 186.00K	€ 1.94M
Total Expenses	-	€ 74.03M	€ 53.97M	€ 54.04M	€ 74.80M	€ 82.24M
Net Income From Continuing And Discontinued Operation	-	€ 17.23M	€ 21.67M	€ -7.90M	€ -24.42M	€ -18.01M
Normalized Income	-	€ 17.24M	€ 21.78M	€ -7.69M	€ -26.46M	€ -16.71M
Interest Expense	-	€ 9.16M	€ 8.99M	€ 8.73M	€ 8.83M	€ 1.04M
EBIT	-	€ 33.63M	€ 32.99M	€ 1.80M	€ -12.47M	€ -16.41M
EBITDA	-	€ 47.49M	€ 40.36M	€ 7.84M	€ -6.72M	€ -11.93M

Currency in EUR

COSMO Pharmaceuticals N.V. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing